Data / Public companies / North Carolina / Biological products, (no diagnostic substances)
Biological products, (no diagnostic substances) companies in North Carolina: 8 that file annual reports with the SEC
Updated September 30, 2026. Source: SEC Financial Statement Data Sets (sec.gov).
8 companies that file annual reports with the SEC have a business address in North Carolina and the industry code SIC 2836 (Biological products, (no diagnostic substances)), in the SEC Financial Statement Data Sets filed through September 30, 2026. 6 report revenue, a combined $973.5 million. 12.5% of the 8 that report net income show a profit. The largest by revenue is Biocryst Pharmaceuticals Inc ($874.8 million).
The request: Get every company that files with the SEC in North Carolina in the industry Biological products, (no diagnostic substances) (SIC 2836), with its revenue, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- 2836SIC code
- 8Companies with an annual report in the data
- 6Companies that report revenue
- $973.5 millionCombined revenue
- $25.5 millionMedian revenue
- 1 of 8 (12.5%)Reported a net profit
- $2.28 billionCombined total assets
- 2Large accelerated filers
- May 20, 2026Newest annual report filed
Largest by revenue
Latest fiscal year, from each company's annual report. Each name links to the company's page.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc | Durham, NC | $874.8 million | $263.9 million | $514.2 million | 94.1% |
| Fennec Pharmaceuticals Inc. | Research Triangle Park, NC | $44.6 million | $-9,741,000 | $70.6 million | -6.1% |
| Precision Biosciences Inc | Durham, NC | $34.3 million | $-45,724,000 | $154.4 million | -50.1% |
| Pelthos Therapeutics Inc. | Durham, NC | $16.8 million | $-43,319,000 | $130.4 million | Not listed |
| Humacyte, Inc. | Durham, NC | $2 million | $-40,833,000 | $116.4 million | Not listed |
| Prokidney Corp. | Winston-Salem, NC | $893,000 | $-68,986,000 | $335.6 million | 1,075% |
Companies by size of revenue
Companies that report revenue, by the revenue in their latest annual report.
| Revenue | Companies | Share |
|---|---|---|
| Under $10 million | 2 | 33.3% |
| $10 million to $100 million | 3 | 50% |
| $100 million to $1 billion | 1 | 16.7% |
Cities with the most companies
By city of the business address.
Newest annual reports
By the date the company filed its latest annual report with the SEC.
| Company | Filed | Fiscal year ended | Form | Revenue |
|---|---|---|---|---|
| Immunovant, Inc. | May 20, 2026 | March 31, 2026 | 10-K | Not listed |
| Adaptin Bio, Inc. | April 1, 2026 | December 31, 2025 | 10-K | Not listed |
| Humacyte, Inc. | March 27, 2026 | December 31, 2025 | 10-K | $2 million |
| Fennec Pharmaceuticals Inc. | March 27, 2026 | December 31, 2025 | 10-K | $44.6 million |
| Pelthos Therapeutics Inc. | March 19, 2026 | December 31, 2025 | 10-K | $16.8 million |
| Prokidney Corp. | March 18, 2026 | December 31, 2025 | 10-K | $893,000 |
| Precision Biosciences Inc | March 12, 2026 | December 31, 2025 | 10-K | $34.3 million |
| Biocryst Pharmaceuticals Inc | February 26, 2026 | December 31, 2025 | 10-K | $874.8 million |
Filer category
The SEC's size class for the company when it filed.
| Category | Companies | Share |
|---|---|---|
| Non-accelerated filer | 6 | 75% |
| Large accelerated filer | 2 | 25% |
Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.